Allarity Therapeutics logo

Allarity TherapeuticsNASDAQ: ALLR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

21 December 2021

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$1.94 M
-99%vs. 3y high
6%vs. sector
-vs. 3y high
-vs. sector
-99%vs. 3y high
19%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 23:49:01 GMT
$1.37-$0.03(-2.14%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ALLR Latest News

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Urged To Contact The Schall Law Firm
accesswire.com02 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 17, 2022 and July 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 12, 2024.

ALLR DEADLINE NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – ALLR
globenewswire.com02 November 2024 Sentiment: NEGATIVE

NEW YORK, Nov. 02, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR
prnewswire.com02 November 2024 Sentiment: -

NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR) and certain officers.  The class action, filed in the United States District Court for the Southern District of New York, and docketed under 24-cv-06952, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Allarity securities between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

ALLR Deadline: ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit
prnewswire.com01 November 2024 Sentiment: NEGATIVE

NEW YORK , Nov. 1, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the "Class Period"), of the important November 12, 2024 lead plaintiff deadline. So what: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
globenewswire.com30 October 2024 Sentiment: NEGATIVE

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Allarity To Contact Him Directly To Discuss Their Options

ALLR FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – ALLR
globenewswire.com29 October 2024 Sentiment: NEGATIVE

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline.

Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion.
globenewswire.com28 October 2024 Sentiment: NEGATIVE

Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Allarity Therapeutics, Inc. (ALLR)
globenewswire.com28 October 2024 Sentiment: NEGATIVE

LOS ANGELES, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) securities between May 17, 2022 and July 19, 2024, inclusive (the “Class Period”).

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Affected Investors Are Urged To Contact The Schall Law Firm
accesswire.com27 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 17, 2022 and July 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 12, 2024.

ALLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
accesswire.com27 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Allarity securities between May 17, 2022, and July 19, 2024, inclusive (the "Class Period").

What type of business is Allarity Therapeutics?

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

What sector is Allarity Therapeutics in?

Allarity Therapeutics is in the Healthcare sector

What industry is Allarity Therapeutics in?

Allarity Therapeutics is in the Biotechnology industry

What country is Allarity Therapeutics from?

Allarity Therapeutics is headquartered in United States

When did Allarity Therapeutics go public?

Allarity Therapeutics initial public offering (IPO) was on 21 December 2021

What is Allarity Therapeutics website?

https://www.allarity.com

Is Allarity Therapeutics in the S&P 500?

No, Allarity Therapeutics is not included in the S&P 500 index

Is Allarity Therapeutics in the NASDAQ 100?

No, Allarity Therapeutics is not included in the NASDAQ 100 index

Is Allarity Therapeutics in the Dow Jones?

No, Allarity Therapeutics is not included in the Dow Jones index

When was Allarity Therapeutics the previous earnings report?

No data

When does Allarity Therapeutics earnings report?

Next earnings report date is not announced yet